This fundamental analysis of Zydus Lifesciences Ltd. (ZYDUSLIFE) looks at revenue trends, profitability, valuation, and shareholding patterns.
Zydus Lifesciences Revenue Trend
Zydus Lifesciences Ltd.'s FY2026 revenue came in at ₹27,658 Cr, up 19.0% from ₹23,242 Cr in FY2025.
Over the past 10 years, revenue climbed from ₹9,617 Cr to ₹27,658 Cr, a CAGR of 11.1% that most companies would envy.
With ₹27,658 Cr in annual revenue, Zydus Lifesciences Ltd. qualifies as a major player in the pharmaceuticals space.
Revenue growth has now continued for 10 consecutive years, a sustained trend rather than a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹27,658 Cr | +19.0% |
| FY2025 | ₹23,242 Cr | +18.9% |
| FY2024 | ₹19,547 Cr | +13.4% |
| FY2023 | ₹17,237 Cr | +14.1% |
| FY2022 | ₹15,110 Cr | — |
View Zydus Lifesciences Ltd.'s full 10-year revenue trend with CAGR analysis →
Zydus Lifesciences Profitability
Net profit came in at ₹5,124 Cr for FY2026, 13.2% higher than FY2025, a healthy bottom line.
Profitability per rupee of revenue eased, as net margin dipped to 18.5% from 19.5% in FY2025.
Diluted EPS rose to ₹50.09 in FY2026, up from ₹44.97 in FY2025.
Is Zydus Lifesciences Undervalued
Shares of Zydus Lifesciences Ltd. currently trade at ₹1,113.80.
Craytheon calculates intrinsic value using the P/E Ratio and EPS Growth models. Both appear in the Valuation Models cards below.
Valuation Models
Zydus Lifesciences Shareholding Pattern
Promoter holding stands at 75.0%, steady over recent quarters.
FII ownership has slipped to 6.9%, down from 7.3% a year earlier.
Domestic institutional investors (DIIs) held 11.3% as of June 2026, an increase from 10.9% a year earlier.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 75.0% | 6.9% | 11.3% | 6.8% |
| Mar 2026 | 75.0% | 7.0% | 11.2% | 6.9% |
| Dec 2025 | 75.0% | 7.1% | 11.1% | 6.8% |
| Sep 2025 | 75.0% | 7.3% | 10.9% | 6.8% |
Track quarterly shareholding changes for Zydus Lifesciences Ltd. →
Zydus Lifesciences Balance Sheet
Proportional view as of 23 Jul 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹524.07B at the end of FY2026, up 40.9% from ₹372.02B a year earlier.
Intangibles & Goodwill is the largest block at 28.4%, followed by Property, Plant & Equipment at 19.8% and Other Assets at 14.7%.
Equity makes up 56.4% of liabilities and equity, with debt at 23.8% and operating liabilities at 19.7%. Over the year, debt is up 288.9% and equity is up 12.2%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 66.31B |
| Receivables | 54.16B |
| Inventories | 56.28B |
| Property, Plant & Equipment | 103.96B |
| Investments | 17.64B |
| Intangibles & Goodwill | 148.75B |
| Other Assets | 76.96B |
| Category | Value |
|---|---|
| Equity | 295.82B |
| Short-term Debt | 86.40B |
| Long-term Debt | 38.56B |
| Trade Payables | 28.45B |
| Other Liabilities | 74.83B |
What Stands Out About Zydus Lifesciences
Here's the picture Zydus Lifesciences Ltd. (ZYDUSLIFE) presents for fundamental analysts.
FY2026 revenue landed at ₹27,658 Cr, up 19.0% year-over-year.
Revenue has compounded at 11.1% annually over the past 10 years.
Profitability remains solid, with a net margin of 18.5% and net income of ₹5,124 Cr.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Zydus Lifesciences Ltd.'s detailed profile on Craytheon.